LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

• Published in: Cell reports (Cambridge) Vol. 39; no. 7; p. 110812
• Main Authors: Westendorf, Kathryn, Žentelis, Stefanie, Wang, Lingshu, Foster, Denisa, Vaillancourt, Peter, Wiggin, Matthew, Lovett, Erica, van der Lee, Robin, Hendle, Jörg, Pustilnik, Anna, Sauder, J. Michael, Kraft, Lucas, Hwang, Yuri, Siegel, Robert W., Chen, Jinbiao, Heinz, Beverly A., Higgs, Richard E., Kallewaard, Nicole L., Jepson, Kevin, Goya, Rodrigo, Smith, Maia A., Collins, David W., Pellacani, Davide, Xiang, Ping, de Puyraimond, Valentine, Ricicova, Marketa, Devorkin, Lindsay, Pritchard, Caitlin, O’Neill, Aoise, Dalal, Kush, Panwar, Pankaj, Dhupar, Harveer, Garces, Fabian A., Cohen, Courtney A., Dye, John M., Huie, Kathleen E., Badger, Catherine V., Kobasa, Darwyn, Audet, Jonathan, Freitas, Joshua J., Hassanali, Saleema, Hughes, Ina, Munoz, Luis, Palma, Holly C., Ramamurthy, Bharathi, Cross, Robert W., Geisbert, Thomas W., Menachery, Vineet, Lokugamage, Kumari, Borisevich, Viktoriya, Lanz, Iliana, Anderson, Lisa, Sipahimalani, Payal, Corbett, Kizzmekia S., Yang, Eun Sung, Zhang, Yi, Shi, Wei, Zhou, Tongqing, Choe, Misook, Misasi, John, Kwong, Peter D., Sullivan, Nancy J., Graham, Barney S., Fernandez, Tara L., Hansen, Carl L., Falconer, Ester, Mascola, John R., Jones, Bryan E., Barnhart, Bryan C.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 17.05.2022; The Authors; Elsevier
• Subjects: Antibodies, Monoclonal - chemistry; Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal - therapeutic use; Antibodies, Neutralizing - chemistry; Antibodies, Neutralizing - pharmacology; Antibodies, Neutralizing - therapeutic use; Antibodies, Viral; COVID-19; COVID-19 Drug Treatment; CP: Microbiology; Epitopes; Humans; neutralizing antibody; SARS-CoV-2; variant of concern; COVID-19; neutralizing antibody; variant of concern; SARS-CoV-2; CP: Microbiology

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 (COVID-19) when administered early. However, SARS-CoV-2 variants of concern (VOCs) have negatively affected therapeutic use of s...